Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review - Isabel Heidegger, Claudia Kesch, Alexander Kretschmer, Igor Tsaur, Francesco Ceci, Massimo Valerio, Derya Tilki, Giancarlo Marra, Felix Preisser, Christian D. Fankhauser, Fabio Zattoni, Peter Chiu, Ignacio Puche-Sanz, Jonathan Olivier, Roderik C. N. van den Bergh, Veeru Kasivisvanathan, Andreas Pircher, Irene Virgolini, Giorgio Gandaglia, 2022 (sagepub.com)
Looks like some retrospective studies have been taking place around 177Lu-PSMA-617 with some clues given as to what biomarkers indicate best treatment strategies for Prostate cancer. NOX-66 is mentioned a couple of times in this article with some possible flags for increased response and even how prior treatment with androgen receptor signaling inhibitors (ARSI) reduced OS. This biomarker study could come in handy if LUPIN goes any further.
Lutetium-177 PSMA, or LuPSMA, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $11.41K | 108.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 123424 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |